Zobrazeno 1 - 4
of 4
pro vyhledávání: '"F317L mutation"'
Publikováno v:
Clinical Management Issues, Vol 5, Iss 5S, Pp 21-25 (2015)
In 1997, a forty-three years old woman was diagnosed with CML and treated with alfa-Interferon, achieving complete haematological response (CHR). Three years later, patient was switched to hydroxiurea due to thyroid toxicity. For logistic reasons, th
Externí odkaz:
https://doaj.org/article/566c97955e024e39ad26045bf2328822
Publikováno v:
Clinical Management Issues; Vol 5, No 5S (2011); 21-25
Clinical Management Issues, Vol 5, Iss 5S, Pp 21-25 (2015)
Clinical Management Issues, Vol 5, Iss 5S, Pp 21-25 (2015)
In 1997, a forty-three years old woman was diagnosed with CML and treated with alfa-Interferon, achieving complete haematological response (CHR). Three years later, patient was switched to hydroxiurea due to thyroid toxicity. For logistic reasons, th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c5347f08d8cefd840f2ff28e4c1d4ad
https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1129
https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1129
Publikováno v:
Biomarker Insights
Biomarker Insights, Vol 2015, Iss Suppl. 3, Pp 43-47 (2015)
Biomarker Insights, Vol 10s3 (2015)
Biomarker Insights, Vol 2015, Iss Suppl. 3, Pp 43-47 (2015)
Biomarker Insights, Vol 10s3 (2015)
The introduction of tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML) has significantly increased survival rate and quality of life for patients with CML. Despite the high efficacy of imatinib, not all patients bene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84490f6a56d9e9b663a763a132e36cd8
https://pubmed.ncbi.nlm.nih.gov/26673003
https://pubmed.ncbi.nlm.nih.gov/26673003
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.